Evidence that vitamin D supplements help protect against COVID-19 and its complications emerged early in the pandemic. Following confirmation that low levels of this nutrient are associated with an increased risk of coronavirus infection, Spanish doctors showed that high-doses cut the risk of death from the virus by 60 percent. Since then, despite ongoing mainstream media claims led by CNN and others that vitamin D supposedly doesn’t protect against COVID-19, the scientific evidence in the nutrient’s favor has continued to grow. Now, a new study from Italy has revealed what its researchers describe as ‘definitive evidence’ that vitamin D supplementation protects against COVID-19-related intensive care unit (ICU) hospitalization.
The Italian researchers note that various studies have found links between vitamin D deficiency and COVID-19-related outcomes. Taking the form of a meta-analysis and trial sequential analysis, the purpose of this new study was therefore to verify the existence of a clear and definitive association between vitamin D supplementation and its effect on COVID-19-related risk of death and ICU hospitalization.
The researchers analyzed five randomized controlled trials involving a total of 1,308 hospitalized COVID-19 patients. The trials employed a variety of different vitamin D doses. In one trial patients were given either 1,000 IU or 5,000 IU of vitamin D for fourteen days. Another trial randomly assigned patients to receive a single 200,000 IU dose of vitamin D3 or a placebo. In a third trial, patients in the vitamin D group took 21,280 IU per day on days one, three, and seven, and then a weekly dose until either they were discharged from hospital or admitted to an ICU. For comparison, a separate group of patients in this trial took no vitamin D at all. A fourth trial administered 21,620 IU of vitamin D to patients on day one, then 10,810 IU on days three, seven, fifteen, and thirty, or a placebo, while in a fifth trial patients received either 2,000 IU or 10,000 IU per day of vitamin D.
After analyzing the five trials, the researchers concluded that their results suggest an ‘indisputable association’ between vitamin D supplementation and a protective effect against ICU admission. Regarding the different dosage protocols employed, they propose that giving 21,620 IU of vitamin D to on day one, followed by 10,810 IU on days three, seven, fifteen, and thirty, could be the most effective approach for hospitalized COVID-19 patients. On the question of whether vitamin D can reduce the risk of death in such patients, while they acknowledge there is evidence of this, they suggest that further studies are needed.
Even prior to this latest study it was already clear that vitamin D deficiency predisposes to COVID-19 and its complications. Scientists in the United States have found 60 percent higher rates of coronavirus infection among people low in the nutrient, for example. An Israeli study has further shown that people deficient in vitamin D are up to 14 times more likely to fall severely ill when contracting the virus. Significantly, therefore, research from Spain suggests that over 80 percent of hospitalized COVID-19 patients are vitamin D deficient.
Conversely, having an adequate level of vitamin D has been found to reduce complications and death among coronavirus patients. Research suggests that higher levels are associated with a lower incidence and severity of COVID-19. Demonstrating the power of nutrient combinations, a study from Singapore has shown that taking daily doses of vitamin D3 along with magnesium and vitamin B12 can reduce the severity of disease in older patients with afflicted with the virus.
Coming hot on the heels of the United States Patent Office awarding the Dr. Rath Research Institute a game-changing patent on a natural approach for preventing and treating coronavirus infections, the publication of the new Italian study clearly represents yet another threatening shot across the bows to the pharmaceutical ‘business with disease’. Crucially, this comes at a time when the COVID-19 vaccine profit model is already breaking down.
Having seen its revenue for 2022 reach a record $100 billion, mRNA vaccine maker Pfizer now expects this to decline by as much as 33 percent in the year ahead. Moderna is anticipating an even greater percentage fall in annual sales of its own mRNA vaccine. As the world increasingly learns of the existence of natural alternatives to experimental vaccines and drugs, the revenues of the pharma industry’s COVID-19 profiteers may yet have further still to fall.